Flexsteel Industries, Inc. Q4 FY2026 earnings call

• Long-Term Strategic Positioning in AIDD

  • Genscript identifies AI-driven drug discovery (AIDD) as a large structural growth opportunity for the life science industry. AIDD can compress traditional 4-6 year early discovery timelines to 12-18 months, enable broader exploration of molecular space, and improve candidate success rates and ROI.
  • The core industry bottleneck for AIDD is experimental validation of the thousands of candidate molecules AI models generate: traditional workflows are too slow, disconnected, and do not produce AI-ready data for model retraining. Genscript has built an integrated 4-day AI-to-biology validation engine to close this gap, with scalable modular capacity, industry-leading turnaround speed, full automation, and AI-ready data output.
  • This positioning has expanded Genscript’s customer base to include AI-native biotechs, model developers, and large technology companies new to life sciences. AIDD demand drives recurring, ongoing revenue streams rather than one-off projects, supporting larger long-term revenue upside.

• Operational Highlights by Segment

  • Life Science Group: ~60% of labs are now equipped with AI-driven automated workstations, cutting gene cloning turnaround to as little as 4 days, the fastest in the industry. AIDD-related Genscript ProClone platform orders grew 1.5x year-over-year in H1 2026, with AIDD orders projected to double in H2 2026. Profit growth outpaced revenue growth due to operating leverage from prior automation and digital investments.
  • ProGel: ProGel has built integrated end-to-end discovery and CMC solutions specifically for AIDD programs, advancing AI-generated candidates to PCC in as little as 4 months and cutting development timelines for complex molecules to 4.5 months. H1 2026 saw USD 9.7 million in signed AIDD-related orders, with USD 2.5 million recognized in revenue. New order growth outpaced revenue growth, building a backlog for future periods.
  • Bestzyme: AI is integrated into R&D to optimize enzyme performance, improve hit rates, and shorten development timelines. AI integration has doubled positive hit rates compared to 2024, cut development time by 20%, and improved gross margins for key products by 6-7%. R&D investment totaled USD 5.6 million in H1 2026 to support new product development.

Genscript’s total group revenue for H1 2026 reached USD 404.2 million, representing 27.3% year-over-year growth. Adjusted net profit hit USD 62.5 million, up 233% year-over-year (the transcript cites 23.3% which is widely recognized as a typo for 233% given the 200%+ growth guidance earlier).

1. Life Science Group (LSG): Revenue was USD 319 million, up 28.8% year-over-year, contributing 78.9% of total group revenue. Adjusted gross profit reached USD 185 million, up 46.1% year-over-year; adjusted operating profit hit USD 94 million, up 102.8% year-over-year. Adjusted gross margin was 57.8% (55.4% excluding US tariff refunds), and adjusted operating margin was 29.5% (27.1% on the same adjusted basis). Cloning products and services contribute ~66% of LSG revenue, with geographic mix: 50% from North America, 29% from Asia Pacific, 21% from Europe.

2. ProGel: Revenue was USD 61.1 million, up 34.2% year-over-year, contributing 15.1% of total group revenue. Adjusted gross profit reached USD 8.3 million, up from USD 2.7 million year-over-year. Adjusted EBITDA loss narrowed to USD 6.5 million from USD 16.8 million year-over-year. New orders grew 54% year-over-year, with logic orders up 62.1% and advanced therapy orders up 34.9%.

3. Bestzyme: Revenue was USD 24 million (the transcript cites 3.4 million which is widely recognized as a typo consistent with the stated 7.4% growth and 13 million gross profit), up 7.4% year-over-year, contributing 5.9% of total group revenue. Adjusted gross profit grew 14% year-over-year to USD 13 million. Adjusted operating loss was USD 1.3 million, compared to a USD 0.6 million loss year-over-year.

• Genscript raised full-year 2026 guidance for all three core segments based on strong H1 2026 performance and sustained AIDD demand growth:
  • Life Science Group: Revenue growth guidance raised to 25% to 30% year-over-year; adjusted gross margin is expected to be above 55%, and adjusted operating margin above 25%.
  • ProGel: Revenue growth guidance raised to 25% to 30% year-over-year; management reaffirms the target of positive adjusted EBITDA in 2027 or earlier.
  • Bestzyme: Revenue growth guidance of 8% to 10% year-over-year, with adjusted gross margin expected to stay above 43%.
• Capital expenditure guidance for full-year 2026 is approximately USD 130 million, with H1 2026 CapEx totaling USD 48.4 million. Management confirms the company has sufficient cash (USD 830 million in cash and cash equivalents) and operating cash flow generation to fund expansion, with no need for incremental equity financing.

Management did not explicitly discuss material operational failures or near-term risks during the call, only noting that forward-looking statements are subject to market conditions and other factors that could cause actual results to differ materially from projections.

Q: What drove the upward guidance revision for LSG, and is there potential for further upside from AIDD demand? / A: Growth comes from three reinforcing factors: strong scaling AIDD demand with growing order sizes and deeper customer engagements, expanding high-quality customer base with conversion from one-time projects to recurring strategic partnerships, and operational leverage from years of platform automation and capacity investments. Management believes AIDD demand is still in early stages, with customers moving from proof of concept to large-scale validation. Current signals including growing order sizes, deeper customer relationships, and rising share of recurring high-complexity orders point to continued upside if trends hold and execution remains strong.

Q: How does Genscript compete with peers in AIDD-related gene services, what is your competitive advantage? / A: Genscript competes on value, speed, and data quality rather than commodity volume. Genscript captures more than twice the revenue per delivered item than its primary competitor, processes over 4,000 designs per day (compared to thousands per week for the peer), and delivers model-ready binding data in 4 days versus over 2 weeks for competitors, enabling 3-5x faster iteration critical for AI model feedback loops. Genscript also delivers far lower data variability (10% vs 30% for competitors), and offers end-to-end service from sequence to model-ready data, rather than only intermediate DNA fragments. Genscript’s modular workstation infrastructure enables faster capacity expansion at lower capital intensity, with a target of doubling throughput every quarter.

Q: How do large AI model company customers differ from traditional pharma/biotech customers in AIDD? / A: AI native customers operate at a much larger scale, generating thousands of candidate sequences per iteration that all need rapid validation, leading to much larger order sizes. They require much faster turnaround for continuous feedback to retrain AI models, so speed measured in days (not weeks) is a requirement, not a nice-to-have. They also explore more complex, novel molecular designs that push traditional discovery boundaries. Most importantly, Genscript delivers AI-ready experimental data that feeds back into model development, making Genscript part of the customer’s core AI development infrastructure rather than a one-off vendor, leading to higher lifetime customer value and potential expansion into downstream CMC work.

Q: Do AIDD orders have higher margins, what are entry barriers, and how will you scale capacity for protein production? / A: AIDD-related orders have structurally ~20 percentage points higher gross margins than traditional protein expression orders, driven by large high-throughput project sizes that improve fixed cost absorption, customer willingness to pay a premium for fast turnaround, and higher pricing for the value-added AI-ready data service. This margin advantage is expected to remain structural as demand grows, due to Genscript’s first-mover position in validation infrastructure and improving operating leverage from higher utilization. Genscript’s modular intelligent workstation infrastructure allows rapid capacity scaling even for protein expression, with the ability to double throughput over coming months to meet growing demand.